8-K: Treace Medical Concepts Announces Preliminary 2024 Results, Revenue Up 12%

Treace Medical Concepts reported preliminary full-year 2024 revenue of $209.0 to $209.4 million, a 12% increase year-over-year, and added approximately 280 new active surgeons.

Summary

• Treace Medical Concepts announced preliminary unaudited financial results for the fourth quarter and full year of 2024.
• The company's preliminary revenue for the fourth quarter is between $68.4 million and $68.8 million, representing a 10% increase at the midpoint compared to the same period in 2023.
• Full-year 2024 preliminary revenue is estimated to be between $209.0 million and $209.4 million, a 12% increase at the midpoint compared to the previous year.
• This full-year revenue is in line with the previously provided guidance range of $204 million to $211 million.
• Treace added approximately 280 new active surgeons in 2024, ending the year with about 3,135 active surgeons, a 10% increase year-over-year.
• The company estimates that approximately 31% of the 10,000 U.S. surgeons performing bunion surgery are now using their Lapiplasty procedure.
• Treace plans to provide 2025 financial guidance during its fourth quarter 2024 earnings conference call scheduled for February 27, 2025.
• The company is expecting breakeven adjusted EBITDA for the full year 2025 and cash flow breakeven in 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increasing surgeon adoption, and a clear path to profitability. The company is executing well and is positioned for continued success.

Positives

• The company achieved a 12% revenue growth for the full year 2024.
• Treace has a strong growth trajectory with a 5-year revenue CAGR of 40%.
• The company is expanding its comprehensive bunion portfolio with new product launches.
• Treace is seeing increased adoption of its Lapiplasty procedure by surgeons.
• The company is focused on driving profitability and expects to reach breakeven adjusted EBITDA in 2025.
• Treace has a strong R&D pipeline with future designs targeting additional procedures.
• The company has a unique, highly scalable model with high margin, sterile implant kits and low cost, reusable instruments.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company is still operating at a loss, although they are expecting to reach breakeven adjusted EBITDA in 2025.
• The company's preliminary 2024 adjusted EBITDA loss is expected to improve by approximately 50% compared to 2023.

Risks

• The preliminary financial results are subject to change based on the completion of the company's financial and operating closing procedures and customary audit procedures.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company operates in a competitive and rapidly changing environment.
• The company's future performance is subject to a high degree of uncertainty and risk.

Future Outlook

Treace expects continued strong revenue growth in 2025 and beyond, driven by new product launches, increased surgeon adoption, and sales rep productivity. The company anticipates achieving breakeven adjusted EBITDA for full-year 2025 and free cash flow breakeven in 2026.

Management Comments

• John T. Treace, CEO, stated that the company closed 2024 with new product announcements and 12% annual revenue growth, positioning them for continued growth in 2025 and beyond.
• The CEO also mentioned that they are excited to enter 2025 with multiple innovative product launches, building upon their comprehensive bunion solutions.

Industry Context

Treace is operating in the foot and ankle market, which is one of the fastest-growing sectors in orthopaedics. The company is focused on the bunion subsegment, which is a large and underserved market. Treace's technology and direct sales approach are aimed at capturing a significant share of this market.

Comparison to Industry Standards

• Treace's 5-year revenue CAGR of 40% indicates a strong growth trajectory compared to many established medical device companies.
• The company's focus on a specific niche (bunion correction) allows for a more targeted approach than companies with broader product portfolios.
• The company's direct sales model is a key differentiator compared to companies that rely on distributors.
• The company's Lapiplasty procedure is gaining market share, with approximately 31% of U.S. bunion surgeons using it, suggesting a competitive advantage over traditional methods.
• The company's expectation of breakeven adjusted EBITDA in 2025 is a positive sign, as many growth-stage medical device companies struggle with profitability.

Stakeholder Impact

• Shareholders can expect continued revenue growth and a path to profitability.
• Surgeons will have access to new and innovative bunion correction technologies.
• Patients will benefit from improved surgical outcomes and faster recovery times.

Next Steps

• Treace will provide 2025 financial guidance during its fourth quarter 2024 earnings conference call on February 27, 2025.
• The company will continue to launch new products in the second half of 2024 and 2025.
• Treace will continue to expand its surgeon customer base and drive penetration into the overall bunion market.

Key Dates

Keywords

Lapiplasty, bunion, surgery, medical devices, revenue, surgeons, orthopaedics, financial results, EBITDA, growth